Pathos AI, a New York drug development startup, raised $365 million in a Series D at a $1.6 billion valuation. The round represents investors’ continued interest in platforms using AI for drug development. The financing brings Pathos AI’s total funding to around $467 million, per PitchBook data. Pathos AI did not disclose Series D investors. Backers in prior rounds included New Enterprise Associates, Revolution and Builders VC, PitchBook says. Pathos AI last raised $62 million in 2024. Pathos AI was launched in 2020 by executives at Chicago-based precision medicine company Tempus, which went public last year. Tempus CEO and serial entrepreneur Eric Lefkofsky and chief operating officer Ryan Fukushima are listed as Pathos AI chairman and board member, respectively, on the company’s website. Iker Huerga, a Tempus and AstraZeneca alum, joined Pathos AI as CEO earlier this month. Pathos AI says it has developed an AI-enabled platform to develop oncology drugs. The new financing will support advancing the company’s clinical-stage pipeline and further building out its platform.

Full exclusive : Pathos AI, which uses AI to develop oncology drugs, raised a $365 million Series D at a $1.6 billion valuation, bringing its total funding to $467 million, per PitchBook.